SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sharon Bio-Medicine rises on getting nod from EDQM for Plant at Taloja in Navi Mumbai

27 May 2014 Evaluate

Sharon Bio-Medicine is currently trading at Rs. 45.20, up by 0.10 points or 0.22% from its previous closing of Rs. 45.10 on the BSE.

The scrip opened at Rs. 46.00 and has touched a high and low of Rs. 46.60 and Rs. 45.10 respectively. So far 124446 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 57.95 on 21-Feb-2014 and a 52 week low of Rs. 27.27 on 20-Nov-2013.

Last one week high and low of the scrip stood at Rs. 50.65 and Rs. 43.80 respectively. The current market cap of the company is Rs. 481.39 crore.

The promoters holding in the company stood at 60.20% while Non-Institutions held 39.80% stake in the company.

Sharon Bio-Medicine’s Active Pharma Ingredient manufacturing Plant at Plot No. L-6, MIDC, Taloja, near Navi Mumbai District  Raigad, Maharashtra has been approved by European Directorate for the Quality of Medicines & Healthcare (EDQM) Council of Europe for complying with the certificate of suitability, as well as the implementation of a suitable Quality Management System based on the Good Manufacturing Practice as laid down in the EU Rules governing Medicinal Product in the European Union, the Company operates in accordance with the requirements of the Resolution AP-CSP (07) 1.

Earlier, the company had completed expansion in its three manufacturing facilities. The total investment in expansion has been incurred to the tune nearly Rs 125 crore. In Dehradun Formulation plant, the expanded expenditure has been around Rs 85 crore whereas capacity of the plant has been increased more than double. Similarly, other plants’ capacity had been added between 30-50%.

Sharon Bio-Medicine’s Toxicology Laboratories is an independent cost centre and is approved by Department of Science & Technology, Government of India. Government of India has approved Good Laboratory Certificate to SA-FORD which is valid as per OECD Countries - GLP studies.

Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×